It's easy to identify shrinking market opportunities for most companies in many industries throughout the world, from air travel to homebuilding, but finding growing markets is far trickier. In 2007, IMS Health
This category of treatments helps the unfortunately burgeoning number of diabetics in the U.S. and worldwide. Earlier this week, the Centers for Disease Control and Prevention (CDC) revealed that in just the past two years, the number of U.S. diabetics grew by a whopping 3 million people (14%), to 24 million patients. According to the CDC, there are another 57 million U.S. patients currently at high risk of sliding into full-blown diabetes as well.
A number of drugmakers are now poised to capitalize on the trend. Pharmaceuticals like Eli Lilly, Novo Nordisk
The CDC reported that 29% of type 1 and type 2 diabetics currently taking medication in the U.S. used insulin, while more than 60% of diabetics were treated by pills such as Merck's
There are multiple other new and innovative diabetes drugs in development, from MannKind's
While many drugmakers can give investors exposure to the growing prevalence of diabetes, the best large-cap pure-play anti-diabetes drugmaker is Novo Nordisk, which provides a wide variety of treatments for the disease. As the CDC report this week unfortunately reminded us, the market for its compounds won't be dwindling anytime soon.
More from The Motley Fool
Novo Nordisk A/S Slogs Through the Year
It was another lackluster quarter from the diabetes specialist.
The 3 Best Diabetes Stocks to Buy in 2018
Not all diabetes stocks are created equally.
Here's Why Novo Nordisk A/S Gained 12% in August
Last summer, the diabetes-focused pharmaceutical issued distressing guidance due to pricing pressure worries, but the forecast troubles failed to arrive.